Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Cigarette smoking is a significant risk factor for cardiovascular disease (CVD) and is the leading cause of premature mortality in the US. The detrimental effects of smoking on vascular dysfunction are attributed to the effects of smoke itself and the inflammatory responses it induces. Smoking cessation restores vascular function by alleviating these stress responses. However, smoking cessation with nicotine replacement therapy (NRT), the prevailing approach to mitigate tobacco dependence, fails to allow full restoration of vascular function. Thus, a critical public health problem exists to understand how NRT prevents restoration of vascular function and how these NRT-mediated impairments can be overcome by using gamma-tocopherol (g-T) as an innovative co-therapy. The objective of this study is to conduct a clinical intervention trial that aims to reduce CVD risk by defining how smoking cessation and g-T restore vascular function. The hypothesis is that smoking cessation and dietary g-T supplementation will synergistically restore smoking-induced impairments in vascular function by ameliorating oxidative/nitrosative stress responses, and that g-T will facilitate full restoration of vascular function otherwise precluded by NRT. A placebo-controlled, g-T intervention study will be conducted in cigarette smokers undergoing nicotine-free or NRT smoking cessation. Prior to and after 24 h and 7 days of placebo or g-T administration, vascular function will be evaluated using a non-invasive ultrasound technique and an array of antioxidants and biomarkers for vascular inflammation and oxidative/nitrosative stress responses will be assessed. Collectively, these studies will help identify how vascular function is regulated in individuals undergoing smoking cessation, and whether g-T can be used as a strategy to better improve vascular function during smoking cessation.
| Condition | Intervention | Phase |
|---|---|---|
|
Endothelial Dysfunction |
Other: Nicotine Replacement Therapy (NRT) Dietary Supplement: Gamma-Tocopherol Other: Placebo Behavioral: Smoking cessation |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Cardioprotective Synergy of Smoking Cessation and γ-Tocopherol in Restoring Vascular Endothelial Function |
- Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0 [ Time Frame: Day 0 and 7 of intervention ] [ Designated as safety issue: No ]Flow-mediated dilation (FMD) of the brachial artery is measured to assess vascular endothelial function. FMD is obtained by monitoring change in vessel diameter before and after brachial artery occlusion with a blood pressure cuff. The unit of FMD is % and is calculated using the following equation: FMD = [(peak dilation at post occlusion - vessel diameter at preocclusion)/vessel diameter at preocclusion]*100.
- Absolute Change From Baseline in Plasma Gamma-tocopherol (Vitamin E) at Day 7 From Day 0. [ Time Frame: Day 0 and 7 of intervention ] [ Designated as safety issue: No ]Plasma measurements of gamma-tocopherol was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation.
- Absolute Change From Baseline in Plasma Malondialdehyde at Day 7 From Day 0. [ Time Frame: Day 0 and 7 of intervention ] [ Designated as safety issue: No ]Plasma measurements of malondialdehyde, a marker of lipid peroxidation was assessed in response to smoking cessation and in combination with gamma-tocopherol (vitamin E) supplementation
| Enrollment: | 67 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Placebo + Smoking Cessation
Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
|
Other: Placebo
Participants will take placebo for 7 days
Other Name: Corn oil
Behavioral: Smoking cessation
Participants will quit smoking without any pharmacological aids
|
|
Experimental: Supplement + Smoking Cessation
Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
|
Dietary Supplement: Gamma-Tocopherol
Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
Other Name: Vitamin E
Behavioral: Smoking cessation
Participants will quit smoking without any pharmacological aids
|
|
Experimental: Placebo + Nicotine Replacement Therapy
Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
|
Other: Nicotine Replacement Therapy (NRT)
Participants will quit smoking with nicotine patches
Other Names:
Other: Placebo
Participants will take placebo for 7 days
Other Name: Corn oil
Behavioral: Smoking cessation
Participants will quit smoking without any pharmacological aids
|
|
Experimental: Supplement + Nicotine Replacement Therapy
Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
|
Other: Nicotine Replacement Therapy (NRT)
Participants will quit smoking with nicotine patches
Other Names:
Dietary Supplement: Gamma-Tocopherol
Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
Other Name: Vitamin E
Behavioral: Smoking cessation
Participants will quit smoking without any pharmacological aids
|
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- male or female between 18-60 y,
- premenopausal status for women
- healthy, verified by serum clinical chemistry
- stable body weight (±5 lbs) for 2-mo and BMI 19-30 kg/m2
- non-nutritional supplement user for >2-mo
- free of known diseases including diabetes, CVD, cancer, infections, HIV/AIDS, hepatitis, and bleeding disorders
- resting blood pressure <140/90 mm Hg;
- smokers (≥10 cigarettes/d, ≥1 year)
- maintaining normal exercise patterns (<7 h/week) and willingness to avoid exercise 24 h prior to blood sampling and vascular testing
- willingness to ingest a dietary vitamin E supplement (gamma-tocopherol; 500 mg/d) or a placebo (composed of tocopherol-free corn oil) daily for 1 week.
Exclusion Criteria:
- serum chemistry outside normal limits
- alcohol consumption >3 drinks/d or >10 drinks per week
- nutritional supplement user with past 2 months
- >7 hours/week of exercise
- use of any pharmacological therapy to treat high cholesterol or high blood pressure
- pregnancy, lactation, or initiation or change in hormonal birth control within the previous 3 mo
- use of vasoactive compounds (e.g. erectile dysfunction medication, omega 3-fatty acids, niacin)
- suffering from major psychiatric illnesses
- currently using non-nicotine aids or drugs to quit smoking; or 10) allergy to adhesive tape.
Contacts and Locations| United States, Connecticut | |
| University of Connecticut | |
| Storrs, Connecticut, United States, 06269 | |
| Principal Investigator: | Richard S Bruno, PhD, RD | University of Connecticut |
More Information
No publications provided
| Responsible Party: | Richard Bruno, Associate Professor, University of Connecticut |
| ClinicalTrials.gov Identifier: | NCT01314443 History of Changes |
| Other Study ID Numbers: | H10-212 |
| Study First Received: | March 10, 2011 |
| Results First Received: | December 12, 2012 |
| Last Updated: | March 5, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Connecticut:
|
smoking cessation gamma-tocopherol nicotine-replacement therapy oxidative stress |
Additional relevant MeSH terms:
|
Smoking Habits Gamma-Tocopherol Vitamin E Tocopherols Tocotrienols Nicotine Nicotine polacrilex Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs |
Vitamins Micronutrients Growth Substances Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013